ZA974366B - Potassium, sodium and tris oxaprozin salt pharmaceutical formulations. - Google Patents

Potassium, sodium and tris oxaprozin salt pharmaceutical formulations.

Info

Publication number
ZA974366B
ZA974366B ZA9704366A ZA974366A ZA974366B ZA 974366 B ZA974366 B ZA 974366B ZA 9704366 A ZA9704366 A ZA 9704366A ZA 974366 A ZA974366 A ZA 974366A ZA 974366 B ZA974366 B ZA 974366B
Authority
ZA
South Africa
Prior art keywords
sodium
potassium
pharmaceutical formulations
salt pharmaceutical
tris
Prior art date
Application number
ZA9704366A
Other languages
English (en)
Inventor
Mark E Adams
Subhash Desai
Aziz Karim
Kalidas Paul
Douglas J Schaaf
David J Zold
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of ZA974366B publication Critical patent/ZA974366B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Steroid Compounds (AREA)
ZA9704366A 1996-05-20 1997-05-20 Potassium, sodium and tris oxaprozin salt pharmaceutical formulations. ZA974366B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1903396P 1996-05-20 1996-05-20

Publications (1)

Publication Number Publication Date
ZA974366B true ZA974366B (en) 1998-05-20

Family

ID=21791076

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9704366A ZA974366B (en) 1996-05-20 1997-05-20 Potassium, sodium and tris oxaprozin salt pharmaceutical formulations.

Country Status (20)

Country Link
US (1) US6030643A (xx)
EP (1) EP0901372B1 (xx)
JP (1) JP4185974B2 (xx)
KR (1) KR20000015865A (xx)
CN (1) CN1129429C (xx)
AT (1) ATE299699T1 (xx)
AU (1) AU718030B2 (xx)
BR (1) BR9710448A (xx)
CA (1) CA2255064C (xx)
CZ (1) CZ370298A3 (xx)
DE (1) DE69733752T2 (xx)
ES (1) ES2248850T3 (xx)
IL (1) IL126998A (xx)
NO (1) NO985414L (xx)
NZ (1) NZ332861A (xx)
PL (1) PL330145A1 (xx)
RU (1) RU2197244C2 (xx)
TW (1) TW586929B (xx)
WO (1) WO1997044022A1 (xx)
ZA (1) ZA974366B (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1233755T3 (da) * 1999-09-29 2007-10-29 Scherer Technologies Inc R P Hydrolyseret cellulosegranuleringer af salte af lægemidler
US6497157B1 (en) * 1999-11-29 2002-12-24 Distek, Inc. Intrinsic dissolution apparatus with stationary sample holder
FR2828810B1 (fr) * 2001-08-27 2005-10-07 Lvmh Rech Composition cosmetique a effet tenseur contenant un polymere d'origine naturelle et un agent hydratant polyhydroxyle
KR100574554B1 (ko) * 2004-05-28 2006-04-27 한미약품 주식회사 니아신의 경구투여용 서방성 조성물
AU2006228869A1 (en) * 2005-03-30 2006-10-05 Astion Pharma A/S Oxaprozin or a closely related compound for the treatment of eczema
PE20061303A1 (es) * 2005-03-30 2006-12-07 Astion Dev As Composicion farmaceutica que comprende oxaprozina
WO2006130726A2 (en) * 2005-06-01 2006-12-07 Teva Pharmaceutical Industries, Ltd. Use of ladostigil for the treatment of multiple sclerosis
US8697125B2 (en) 2007-02-01 2014-04-15 Takeda Pharmaceutical Company Limited Tablet preparation without causing a tableting trouble
SG11201405353VA (en) * 2012-03-22 2014-09-26 Transtech Pharma Llc Tris(hydroxymethyl)aminomethane salts of a small-molecule glp1r agonist and pharmaceutical compositions and uses thereof
EP3275433A1 (en) 2016-07-29 2018-01-31 Som Innovation Biotech S.L. Sustained release composition comprising micronized tolcapone

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1206403A (en) * 1966-12-15 1970-09-23 Wyeth John & Brother Ltd Oxazoles
US3578671A (en) * 1967-11-06 1971-05-11 Wyeth John & Brother Ltd Oxazoles
US3998815A (en) * 1974-06-24 1976-12-21 Interx Research Corporation 1-hydrocarbonoyloxymethyl-3-carbamoyl or 3-carboethoxy-pyridinium salts
US4190584A (en) * 1976-08-13 1980-02-26 John Wyeth & Brother Limited Process for preparing oxazoles
GB2097389B (en) * 1981-04-28 1984-11-28 Wyeth John & Brother Ltd Oxazole derivative
IE52909B1 (en) * 1981-04-28 1988-04-13 Wyeth John & Brother Ltd Oxazole derivatives
US4385049A (en) * 1981-05-12 1983-05-24 K-V Pharmaceutical Company Stable high internal phase ratio topical emulsions
US4599359A (en) * 1982-12-09 1986-07-08 Stephen A. Cooper Hydroxyzine-containing analgesic combinations
GB8329326D0 (en) * 1983-11-03 1983-12-07 Wyeth John & Brother Ltd Oxazole derivatives
IT1204751B (it) * 1986-01-03 1989-03-10 Therapicon Srl Derivati idrosolubili dell'acido 4,5 -difenil- 2 -ossazolpropionico,loro preparazione ed utilizzo in composizioni farmaceutiche
GB8630273D0 (en) * 1986-12-18 1987-01-28 Til Medical Ltd Pharmaceutical delivery systems
US5059626A (en) * 1988-07-25 1991-10-22 Applied Analytical Industries, Inc. Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
US5350769A (en) * 1990-10-30 1994-09-27 Ss Pharmaceutical Co., Ltd. Antiinflammatory gel preparation
AU7604194A (en) * 1993-09-07 1995-03-27 Procter & Gamble Company, The Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agents and caffeine
EP0719156A1 (en) * 1993-09-07 1996-07-03 The Procter & Gamble Company Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive

Also Published As

Publication number Publication date
US6030643A (en) 2000-02-29
DE69733752D1 (de) 2005-08-25
IL126998A (en) 2003-12-10
CA2255064C (en) 2006-10-10
AU718030B2 (en) 2000-04-06
BR9710448A (pt) 1999-08-17
DE69733752T2 (de) 2006-06-01
CZ370298A3 (cs) 1999-05-12
PL330145A1 (en) 1999-04-26
NZ332861A (en) 2000-08-25
IL126998A0 (en) 1999-09-22
KR20000015865A (ko) 2000-03-15
ATE299699T1 (de) 2005-08-15
TW586929B (en) 2004-05-11
CA2255064A1 (en) 1997-11-27
WO1997044022A1 (en) 1997-11-27
NO985414L (no) 1999-01-19
CN1225580A (zh) 1999-08-11
JP2001503734A (ja) 2001-03-21
CN1129429C (zh) 2003-12-03
EP0901372A1 (en) 1999-03-17
RU2197244C2 (ru) 2003-01-27
ES2248850T3 (es) 2006-03-16
JP4185974B2 (ja) 2008-11-26
EP0901372B1 (en) 2005-07-20
AU3059797A (en) 1997-12-09
NO985414D0 (no) 1998-11-20

Similar Documents

Publication Publication Date Title
MX9705569A (es) Inhibidores de adhesion celular.
SG158733A1 (en) Cell adhesion inhibitors
FI962154A (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
SI0725779T1 (xx)
MX9800348A (es) Inhibidores de adhesion celular.
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
ZA943744B (en) Therapeutic substituted guanidines
GR970300016T1 (en) Lactobacillus strains of human origin, their compositions and uses thereof
GB2288732B (en) Pharmaceutical compositions
DE69905170D1 (en) Thiazolopyrimidinderivate
ZA98214B (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1.
IL127918A0 (en) Novel amino sugar and related sugar derivatives of indolylopyrrolocarbazoles their use as antitumor agents and pharmaceutical formulations
YU13301A (sh) Muskarinski agonisti i antagonisti
ZA974366B (en) Potassium, sodium and tris oxaprozin salt pharmaceutical formulations.
BG102250A (en) The use of marigold-extracted glycosides for the treatment of psoriasis
EP1032556A4 (en) PHARMACEUTICALLY EFFECTIVE COMPOUNDS AND METHODS OF THEIR APPLICATION
PL316656A1 (en) Free halophantrin base for use in treating marsh-fever and compositions containing same
MXPA94009086A (es) Guanidinas sustituidas terapeuticas.
MX9403088A (es) Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
NZ330944A (en) Peptide derivatives
GB9505082D0 (en) Medicament
IL111804A0 (en) Pharmaceutical compositions comprising dimeticone for the treatment of constipation
NZ217356A (en) Benzamide derivatives and pharmaceutical compositions
MD457G2 (ro) Derivaţi noi de naftiridină, procedeu de preparare a lor, compoziţii farmaceutice care le conţin, utilizarea lor ca medicamente de antireproducere
GB9921985D0 (en) Medicaments containing pantothenic acid